Developing Therapeutics and Vaccines for Coronaviruses
https://www.niaid.nih.gov/diseases-conditions/coronaviruses-therapeutics-vaccines
NIAID has also supported the clinical testing of two promising antibody-based therapeutics, which prevent the virus from infecting and entering cells. NIAID conducted a phase 1 clinical trial of SAB-301, an experimental MERS treatment developed from cattle that make human antibodies. This was shown to be safe and well tolerated in healthy adults. More recently, NIAID supported a Phase I clinical trial of a combination of two monoclonal antibodies, REGN3048 and REGN 3051, and demonstrated this combination was also safe and well tolerated. Planning for follow on Phase 2/3 efficacy studies using SAB-301 is currently ongoing with partners where MERS is endemic, including the Kingdom of Saudi Arabia.
NIH clinical trial of investigational vaccine for COVID-19 begins
Read more about developing therapeutics and vaccines for coronaviruses
NIAID has also supported the clinical testing of two promising antibody-based therapeutics, which prevent the virus from infecting and entering cells. NIAID conducted a phase 1 clinical trial of SAB-301, an experimental MERS treatment developed from cattle that make human antibodies. This was shown to be safe and well tolerated in healthy adults. More recently, NIAID supported a Phase I clinical trial of a combination of two monoclonal antibodies, REGN3048 and REGN 3051, and demonstrated this combination was also safe and well tolerated. Planning for follow on Phase 2/3 efficacy studies using SAB-301 is currently ongoing with partners where MERS is endemic, including the Kingdom of Saudi Arabia.
NIH clinical trial of investigational vaccine for COVID-19 begins